PURPOSE: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is emerging to be a useful tool in supporting the diagnosis of AIE. In this study, we describe the metabolic patterns on F-18 FDG PET imaging in AIE. METHODS: Twenty-four antibody-positive patients (anti-NMDA-15, anti-VGKC/LGI1-6, and anti-GAD-3), 14 females and 10 males, with an age range of 2-83 years were included in this study. Each PET study was evaluated visually for the presence of hypometabolism or hypermetabolism and semiquantitatively using Cortex ID (GE) and Scenium (Siemens) by measuring regional Z-scores. These patterns were correlated with corresponding antibody positivity once available. RESULTS: Visually, a pattern of hypometabolism, hypermetabolism, or both in various spatial distributions was appreciated in all 24 patients. On quantitative analysis using scenium parietal and occipital lobes showed significant hypometabolism with median Z-score of -3.8 (R) and -3.7 (L) and -2.2 (R) and -2.5 (L) respectively. Two-thirds (16/24) showed significant hypermetabolism involving the basal ganglia with median Z-score of 2.4 (R) and 3.0 (L). Similarly on Cortex ID, the median Z-score for hypometabolism in parietal and occipital lobes was -2.2 (R) and -2.4 (L) and -2.6 (R) and -2.4 (L) respectively, while subcortical regions were not evaluated. MRI showed signal alterations in only 11 of these patients. CONCLUSION: There is heterogeneity in metabolic topography of AIE which is characterized by hypometabolism most commonly involving the parietal and occipital cortices and hypermetabolism most commonly involving the basal ganglia. Scenium analysis using regional Z-scores can complement visual evaluation for demonstration of these metabolic patterns on FDG PET.
PURPOSE: F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is emerging to be a useful tool in supporting the diagnosis of AIE. In this study, we describe the metabolic patterns on F-18 FDG PET imaging in AIE. METHODS: Twenty-four antibody-positive patients (anti-NMDA-15, anti-VGKC/LGI1-6, and anti-GAD-3), 14 females and 10 males, with an age range of 2-83 years were included in this study. Each PET study was evaluated visually for the presence of hypometabolism or hypermetabolism and semiquantitatively using Cortex ID (GE) and Scenium (Siemens) by measuring regional Z-scores. These patterns were correlated with corresponding antibody positivity once available. RESULTS: Visually, a pattern of hypometabolism, hypermetabolism, or both in various spatial distributions was appreciated in all 24 patients. On quantitative analysis using scenium parietal and occipital lobes showed significant hypometabolism with median Z-score of -3.8 (R) and -3.7 (L) and -2.2 (R) and -2.5 (L) respectively. Two-thirds (16/24) showed significant hypermetabolism involving the basal ganglia with median Z-score of 2.4 (R) and 3.0 (L). Similarly on Cortex ID, the median Z-score for hypometabolism in parietal and occipital lobes was -2.2 (R) and -2.4 (L) and -2.6 (R) and -2.4 (L) respectively, while subcortical regions were not evaluated. MRI showed signal alterations in only 11 of these patients. CONCLUSION: There is heterogeneity in metabolic topography of AIE which is characterized by hypometabolism most commonly involving the parietal and occipital cortices and hypermetabolism most commonly involving the basal ganglia. Scenium analysis using regional Z-scores can complement visual evaluation for demonstration of these metabolic patterns on FDG PET.
Authors: Frank Boesebeck; Oliver Schwarz; Bernhard Dohmen; Ulrike Graef; Thomas Vestring; Corinna Kramme; Christian G Bien Journal: J Neurol Date: 2013-05-17 Impact factor: 4.849
Authors: Mohsin Maqbool; Deanna A Oleske; A H M Huq; Bassel A Salman; Kevin Khodabakhsh; Harry T Chugani Journal: J Child Neurol Date: 2011-05-19 Impact factor: 1.987
Authors: Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent Journal: Brain Date: 2010-06 Impact factor: 13.501
Authors: Florian Wegner; Florian Wilke; Peter Raab; Said Ben Tayeb; Anna-Lena Boeck; Cathleen Haense; Corinna Trebst; Elke Voss; Christoph Schrader; Frank Logemann; Jörg Ahrens; Andreas Leffler; Rea Rodriguez-Raecke; Reinhard Dengler; Lilli Geworski; Frank M Bengel; Georg Berding; Martin Stangel; Elham Nabavi Journal: BMC Neurol Date: 2014-06-20 Impact factor: 2.474
Authors: Nicolas De Leiris; Berangère Ruel; Jean Vervandier; José Boucraut; Stephan Grimaldi; Tatiana Horowitz; Jean Pelletier; Frederique Fluchere; Jacques-Yves Campion; Elsa Kaphan; Eric Guedj Journal: Eur J Nucl Med Mol Imaging Date: 2021-08-31 Impact factor: 9.236
Authors: Stefan Macher; Friedrich Zimprich; Desiree De Simoni; Romana Höftberger; Paulus S Rommer Journal: Front Immunol Date: 2018-11-22 Impact factor: 7.561
Authors: Manon Bordonne; Mohammad B Chawki; Matthieu Doyen; Aurelie Kas; Eric Guedj; Louise Tyvaert; Antoine Verger Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-07 Impact factor: 10.057